Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma

Tumori

Volumn 98, Issue 1, 2012, Pages 45-52

  Buti, Sebastiano ^a   Rovere, Rodrigo Kraft ^b   Donini, Maddalena ^a   Passalacqua, Rodolfo ^a   Pezzuolo, Debora ^c   Buzio, Carlo ^d  

^a CREMONA HOSPITAL   (Italy)

^b Hospital Santo Antonio Blumenau   (Brazil)

^c Ospedale di Carrara   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

Immunological response; Interferon ; Interleukin 2; Lymphocyte; Renal cell carcinoma

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PERIPHERAL LYMPHOCYTE; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNOLOGY; KIDNEY TUMOR; LYMPHOCYTE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEPHRECTOMY; TREATMENT OUTCOME;

EID: 84863223743     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800106     Document Type: Article

References (32)

1. Jeal W, Goa KL: Aldesleukin (recombinant interleukin-2): a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma. Bio Drugs, 7: 285-317, 1997. (Pubitemid 27300118)
2. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE: Interferon alpha-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol, 11: 1368-1375, 1993. (Pubitemid 23199143)
3. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 13: 688-696, 1995.
4. Bordin V, Giani L, Meregalli S, Bukovec R, Vaghi MM, Mandala M, Paolorossi F, Ardizzoia A, Tancini G, Barni S, Frigerio F, Fumagalli L, Bordoni A, Valsuani G, Di Felice G, Dissoni P: Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol Int, 64: 3-8, 2000. (Pubitemid 30224033)
5. Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am, 6 Suppl 1: S55-S57, 2000.
6. Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T: Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am, 6 Suppl 1: S93-S98, 2000.
7. Bukowski RM, Olencki T, Wang Q, Peereboom D, Budd GT, Elson P, Sandstrom K, Tuason L, Rayman P, Tubbs R, McLain D, Klein E, Novick A, Finke J: Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. J Immunother, 20: 301-311, 1997. (Pubitemid 28011542)
8. Hernberg M: Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. Med Oncol, 16: 145-153, 1999.
9. Pavone L, Fanti G, Bongiovanni C, Goldoni M, Alberici F, Bonomini S, Cristinelli L, Buzio C: Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-α in patients with renal cell carcinoma. Med Oncol, 26: 38-44, 2009.
10. Wersall P, Mellstedt H: Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN. Med Oncol, 12: 69-77, 1995.
11. Gohring B, Riemann D, Rebmann U, Heynemann H, Schabel J, Langner J: Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU. Urol Res, 24: 297-303, 1996. (Pubitemid 26361769)
12. Pavone L, Andrulli S, Santi R, Majori M, Buzio C: Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer. Cancer Immunol Immunother, 50: 82-86, 2001. (Pubitemid 32424492)
13. Donskov F, Bennedsgaard KM, Hokland M, Marcussen N, Fisker R, Madsen HH, Fode K, von der Maase H: Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother, 53: 729-739, 2004. (Pubitemid 38962067)
14. Jeong IG, Han KS, Joung JY, Choi WS, Hwang SS, Yang SO, Seo HK, Chung J, Lee KH: Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for matastatic renal cell carcinoma: correlation with response and survival. J Korean Med Sci, 22 Suppl: S122-S128, 2007.
15. Buzio C, Andrulli S, Santi R, Pavone L, Passalacqua R, Potenzoni D, Ferrozzi F, Giocosa R, Vaglio A: Long-term immunotherapy with low-dose interleukin-2 and interferonalpha in the treatment of patients with advanced renal cell carcinoma. Cancer, 92: 2286-2296, 2001. (Pubitemid 33029072)
16. Atzpodien J, Kirchner H, Korfer A, Hadam M, Schomburg A, Menzel T, Deckert M, Franzke A, Volkenandt M, Dallmann I: Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2. Tumour Biol, 14: 354-359, 1993. (Pubitemid 24026186)
17. von Rohr A, Ghosh AK, Thatcher N, Stern PL: Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. Br J Cancer, 67: 163-171, 1993. (Pubitemid 23034943)
18. Moltò L, Carballido J, Manzano L, Martinez-Martin B, Esquivel F, Chafer J, Olivier C, Alvarez-Mon M: Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2. J Immunother, 22: 260-267, 1999. (Pubitemid 29226987)
19. Donskov F, Bennedsgaard KM, Von Der Maase H, Marcussen N, Fisker R, Jensen JJ, Naredi P, Hokland M: Intratumoral and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J of Cancer, 87: 194-201, 2002.
20. Passalacqua R, Buzio C, Buti S, Labianca R, Porta C, Boni C, Rondini E, Camisa R, Sabbatini R, Artioli F, Caminiti C: Adjuvant low-dose interleukin-2 (IL-2) plus interferon-alpha (IFN-α) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC). J Clin Oncol, 25: 965s, Abstract LBA5028, 2007.
21. Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C: Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer. Cancer Immunol Immunother, 59: 553-561, 2010.
22. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol, 6: 655-663, 1982. (Pubitemid 13234762)
23. Fumagalli L, Lissoni P, Di Felice G, Meregalli S, Valsuani G, Mengo S, Rovelli F: Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer, 80: 407-411, 1999. (Pubitemid 29213193)
24. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A: Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother, 26: 394-402, 2003. (Pubitemid 37128551)
25. Caligiuri MA: Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin Oncol, 20 (6 Suppl 9): 3-10, 1993. (Pubitemid 24018747)
26. Raspadori D, Lauria F, Ventura MA, Tazzari PL, Ferrini S, Miggiano MC, Rondelli D, Tura S: Low doses of rIL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas. Ann Hematol, 71: 175-179, 1995.
27. Uhr JW, Scheuermann RH, Street NE, Vitetta ES: Cancer dormancy: opportunities for new therapeutic approaches. Nat Med, 3: 505-509, 1997. (Pubitemid 27198646)
28. Lenardo MJ: Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature, 353: 858-861, 1991.
29. Vlasveld LT, Hekman A, Vyth-Dreese FA, Rankin EM, Scharenberg JG, Voordouw AC, Sein JJ, Dellemijn TA, Rodenhuis S, Melief CJ: A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. Br J Cancer, 68: 559-567, 1993. (Pubitemid 23258462)
30. Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, Giani L, Vaghi M, Ardizzoia A, Gardani GS: Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers, 19: 135-140, 2004. (Pubitemid 39106939)
31. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V: Phase III trial of bevacizumab plus interferon alpha-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol, 28: 2144-2150, 2010.
32. Fishman M, Seigne J: Immunotherapy of metastatic renal cell cancer. Cancer Control, 9: 293-304, 2002. (Pubitemid 34921035)